Vanichapol et al., 2018 - Google Patents
Secretory High‐Mobility Group Box 1 protein affects regulatory T cell differentiation in neuroblastoma microenvironment in vitroVanichapol et al., 2018
View PDF- Document ID
- 3037666856961793982
- Author
- Vanichapol T
- Chiangjong W
- Panachan J
- Anurathapan U
- Chutipongtanate S
- Hongeng S
- Publication year
- Publication venue
- Journal of oncology
External Links
Snippet
Neuroblastoma (NB) is the most common extracranial tumor of childhood with poor prognosis in a high‐risk group. An obstacle in the development of treatment for solid tumors is the immunosuppressive nature of the tumor microenvironment (TME). Regulatory T cells …
- 206010029260 Neuroblastoma 0 title abstract description 78
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hezaveh et al. | Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity | |
| Cao et al. | Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells | |
| Mandula et al. | Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses | |
| Si et al. | Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies | |
| Kumagai et al. | An oncogenic alteration creates a microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells | |
| Sadik et al. | IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression | |
| Kumagai et al. | Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments | |
| Denk et al. | Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy | |
| Zhang et al. | Specific decrease in B-cell-derived extracellular vesicles enhances post-chemotherapeutic CD8+ T cell responses | |
| Choi et al. | Glutamate signaling in hepatic stellate cells drives alcoholic steatosis | |
| Chen et al. | Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8+ T cell exhaustion and curtails anti-PD-1 efficacy | |
| Ren et al. | The R132H mutation in IDH 1 promotes the recruitment of NK cells through CX 3 CL 1/CX 3 CR 1 chemotaxis and is correlated with a better prognosis in gliomas | |
| Vanichapol et al. | Secretory High‐Mobility Group Box 1 protein affects regulatory T cell differentiation in neuroblastoma microenvironment in vitro | |
| Wild et al. | HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer | |
| Wan et al. | miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway | |
| Lu et al. | A novel multi‐epitope vaccine from MMSA‐1 and DKK 1 for multiple myeloma immunotherapy | |
| Wang et al. | CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma | |
| Lin et al. | Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance | |
| Andrews et al. | Concepts collide: genomic, immune, and microbial influences on the tumor microenvironment and response to cancer therapy | |
| Zhang et al. | Amino acids and RagD potentiate mTORC1 activation in CD8+ T cells to confer antitumor immunity | |
| Ma et al. | Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis | |
| Feng et al. | Molecular mechanism underlying the difference in proliferation between placenta‐derived and umbilical cord‐derived mesenchymal stem cells | |
| Mou et al. | Icaritin inhibits the progression of urothelial cancer by suppressing PADI2-mediated neutrophil infiltration and neutrophil extracellular trap formation | |
| Weis-Banke et al. | Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells | |
| Morandi et al. | IL‐10 and ARG‐1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome |